Guardant Health Inc
NASDAQ:GH

Watchlist Manager
Guardant Health Inc Logo
Guardant Health Inc
NASDAQ:GH
Watchlist
Price: 35.1 USD 2.12% Market Closed
Market Cap: 4.3B USD
Have any thoughts about
Guardant Health Inc?
Write Note

Intrinsic Value

GH's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one GH stock under the Base Case scenario is 34.89 USD. Compared to the current market price of 35.1 USD, Guardant Health Inc is Overvalued by 1%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

GH Intrinsic Value
34.89 USD
Overvaluation 1%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Guardant Health Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for GH cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about GH?
Bearish
Neutral
Bullish

Fundamental Analysis

Guardant Health Inc
US
Health Care
Market Cap
4.3B USD
IPO
Oct 4, 2018
Employees
1 373
United States of America
Market Cap
4.3B USD
Industry
Health Care
IPO
Oct 4, 2018

Guardant Health, Inc. is a precision oncology company, engages in treatment of cancer through use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Redwood City, California and currently employs 1,373 full-time employees. The company went IPO on 2018-10-04. The firm is focused on helping conquer cancer through the use of its blood-based tests, data sets, and advanced analytics. The company has developed its Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced-stage cancer. The company also developed its Guardant Reveal liquid biopsy-based test for residual and recurring cancer to address the need for Stage II-II I colorectal cancer. Its Guardant360 test is a molecular diagnostic test measuring 74 cancer-related genes. Its Guardant360 CDx test is a liquid biopsy test measuring 55 cancer-related genes. Its GuardantOMNI test has a broader 500-gene panel, all of which analyze circulating tumor deoxyribonucleic acid (DNA) in the blood. The firm's tests are used by biopharmaceutical companies for a range of applications, including identifying patient populations to accelerate translational science research and clinical trial enrollment, and companion diagnostic.

[ Read More ]

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

AI Assistant
AI Assistant
Ask me anything about Guardant Health Inc

Provide an overview of the primary business activities
of Guardant Health Inc.

What unique competitive advantages
does Guardant Health Inc hold over its rivals?

What risks and challenges
does Guardant Health Inc face in the near future?

Has there been any significant insider trading activity
in Guardant Health Inc recently?

Summarize the latest earnings call
of Guardant Health Inc.

What significant events have occurred
in Guardant Health Inc over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Guardant Health Inc.

Provide P/S
for Guardant Health Inc.

Provide P/E
for Guardant Health Inc.

Provide P/OCF
for Guardant Health Inc.

Provide P/FCFE
for Guardant Health Inc.

Provide P/B
for Guardant Health Inc.

Provide EV/S
for Guardant Health Inc.

Provide EV/GP
for Guardant Health Inc.

Provide EV/EBITDA
for Guardant Health Inc.

Provide EV/EBIT
for Guardant Health Inc.

Provide EV/OCF
for Guardant Health Inc.

Provide EV/FCFF
for Guardant Health Inc.

Provide EV/IC
for Guardant Health Inc.

Show me price targets
for Guardant Health Inc made by professional analysts.

What are the Revenue projections
for Guardant Health Inc?

How accurate were the past Revenue estimates
for Guardant Health Inc?

What are the Net Income projections
for Guardant Health Inc?

How accurate were the past Net Income estimates
for Guardant Health Inc?

What are the EPS projections
for Guardant Health Inc?

How accurate were the past EPS estimates
for Guardant Health Inc?

What are the EBIT projections
for Guardant Health Inc?

How accurate were the past EBIT estimates
for Guardant Health Inc?

Compare the revenue forecasts
for Guardant Health Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Guardant Health Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Guardant Health Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Guardant Health Inc compared to its peers.

Compare the P/E ratios
of Guardant Health Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Guardant Health Inc with its peers.

Analyze the financial leverage
of Guardant Health Inc compared to its main competitors.

Show all profitability ratios
for Guardant Health Inc.

Provide ROE
for Guardant Health Inc.

Provide ROA
for Guardant Health Inc.

Provide ROIC
for Guardant Health Inc.

Provide ROCE
for Guardant Health Inc.

Provide Gross Margin
for Guardant Health Inc.

Provide Operating Margin
for Guardant Health Inc.

Provide Net Margin
for Guardant Health Inc.

Provide FCF Margin
for Guardant Health Inc.

Show all solvency ratios
for Guardant Health Inc.

Provide D/E Ratio
for Guardant Health Inc.

Provide D/A Ratio
for Guardant Health Inc.

Provide Interest Coverage Ratio
for Guardant Health Inc.

Provide Altman Z-Score Ratio
for Guardant Health Inc.

Provide Quick Ratio
for Guardant Health Inc.

Provide Current Ratio
for Guardant Health Inc.

Provide Cash Ratio
for Guardant Health Inc.

What is the historical Revenue growth
over the last 5 years for Guardant Health Inc?

What is the historical Net Income growth
over the last 5 years for Guardant Health Inc?

What is the current Free Cash Flow
of Guardant Health Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Guardant Health Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Guardant Health Inc

Current Assets 1.2B
Cash & Short-Term Investments 895.7m
Receivables 88.5m
Other Current Assets 242.5m
Non-Current Assets 312m
PP&E 270.1m
Intangibles 10.5m
Other Non-Current Assets 31.3m
Current Liabilities 197.3m
Accounts Payable 15.5m
Accrued Liabilities 152.3m
Other Current Liabilities 29.6m
Non-Current Liabilities 1.4B
Long-Term Debt 1.1B
Other Non-Current Liabilities 259.6m
Efficiency

Earnings Waterfall
Guardant Health Inc

Revenue
692.3m USD
Cost of Revenue
-274.7m USD
Gross Profit
417.5m USD
Operating Expenses
-939.7m USD
Operating Income
-522.1m USD
Other Expenses
9.7m USD
Net Income
-512.4m USD

Free Cash Flow Analysis
Guardant Health Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

GH Profitability Score
Profitability Due Diligence

Guardant Health Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
26/100
Profitability
Score

Guardant Health Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

GH Solvency Score
Solvency Due Diligence

Guardant Health Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Positive Net Debt
Long-Term Solvency
54/100
Solvency
Score

Guardant Health Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GH Price Targets Summary
Guardant Health Inc

Wall Street analysts forecast GH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GH is 42.43 USD with a low forecast of 19.19 USD and a high forecast of 63 USD.

Lowest
Price Target
19.19 USD
45% Downside
Average
Price Target
42.43 USD
21% Upside
Highest
Price Target
63 USD
79% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for GH?

Click here to dive deeper.

Dividends

Guardant Health Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for GH is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

GH Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

GH News

Other Videos

See Also

Discover More
What is the Intrinsic Value of one GH stock?

The intrinsic value of one GH stock under the Base Case scenario is 34.89 USD.

Is GH stock undervalued or overvalued?

Compared to the current market price of 35.1 USD, Guardant Health Inc is Overvalued by 1%.

Back to Top